ArticleJournal of nanobiotechnology2026
Ultrasound-stimulated BTO-BSA-gen inhibits implant-associated infections by suppressing bacterial adhesion and potentiating aminoglycosides.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Biofilms render implant-associated infections (IAIs) particularly challenging to manage. Inhibiting bacterial adhesion, the initial stage of biofilm formation, holds great potential in alleviating IAIs. In this work, we proved that the ultrasound(US)-generated electricity provided by barium titanate nanoparticles (BTO) could inhibit bacterial adhesion. Transcriptomics and metabolomics results validated that the BTO under ultrasound reduces the amount of integral membrane molecules in S. aureus and suppresses the expression of toxin molecules. Moreover, ultrasound-generated electricity provided by BTO improved the effectiveness of aminoglycosides through "bioelectric effect". Based on these findings, we further synthesized gentamicin(gen) loaded BTO-BSA (BTO-BSA-Gen), which demonstrated promising bactericidal effects in an ex vivo human skin model. Animal studies show the engineered BTO-BSA-Gen could substantially safeguard implants against bacteremia, consequently diminishing the onset and severity of IAIs. The frequency of hematogenous IAIs decreased significantly from 83.7% to 25% in response to ultrasound following BTO-BSA-Gen administration. This research offers valuable insights for the development of noninvasive, wireless therapies for IAIs treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.